The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets [0.03%]
Jessica K Lee,Julia C F Quintanilha,Kuei-Ting Chen et al.
Jessica K Lee et al.
High concordance (sensitivity 88%) of amplification detection in liquid biopsy vs tissue was associated with higher AmpRatio and ctDNA tumor fraction ≥20%.
Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies [0.03%]
Muhammad Anees,Christopher Sherry,Hyun Y Park et al.
Muhammad Anees et al.
Here, we review the current landscape of liquid biopsy biomarkers for GI cancers, emphasising technological innovations, clinical performance and ongoing trials.
Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability [0.03%]
Fang He,Mostafa Hossam El Din Moawad,Mohamed A Alsaied et al.
Fang He et al.
Biomarker-directed patient selection (e.g., MTAP loss clustering, EZH2/LSD1 activity, methylation and chromatin signatures, and liquid biopsy dynamics of methylation or ctDNA) will be critical to enrich for patients most likely to benefit.
Cascading inertial microfluidics for high-throughput, multi-scale enrichment of tumor cells and intact clusters towards enhanced malignancy diagnosis [0.03%]
Zhixian Zhu,Hui Ren,Zijian Zhang et al.
Zhixian Zhu et al.
While tumor cell-based liquid biopsy enables the detection of single MTCs, but clinical utility is limited by cellular damage and attrition of MTCCs.
Silvia Carrara,Michele Bevere,Donatella Delle Cave et al.
Silvia Carrara et al.
Here we provide a comprehensive overview on liquid biopsy in pancreatic cancer, presenting its current progress, limitations, and future perspectives.
ICP-MS/colorimetric dual-mode detection of circulating tumor cells with dual-aptamer recognition based on gold nanoparticles [0.03%]
Yating Chen,Lina Zheng,Jinchao You et al.
Yating Chen et al.
This combination provides a reliable and flexible analytical platform for CTC liquid biopsy and early tumor diagnosis in clinical settings.
Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liquid biopsy [0.03%]
Sherif B Elsherif,Luyao Shen,Luke Yoon et al.
Sherif B Elsherif et al.
Objectives: To evaluate the concordance between circulating tumor DNA (ctDNA) and imaging in the postoperative surveillance of patients with resected pancreatic ductal adenocarcinoma (PDAC). ...
Clara Chamba,Heavenlight Christopher,Emmanuel Josephat et al.
Clara Chamba et al.
Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants....These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV+ BL and may substantially reduce treatment delays in resource-limited settings. © 2026. The Author(s).
Methylation entropy as a novel dimension in liquid biopsy: enhanced multimodal framework for cancer detection and tissue-of-origin classification [0.03%]
Xiaoqiong Jia,Yongjun Li,Baochen Du et al.
Xiaoqiong Jia et al.
Single tube cell-free transcription and autocatalytic signal amplification based fluorescent biosensor for microRNA detection [0.03%]
Qian Xie,Ming Chen,Zhenyu Lin
Qian Xie
This work presents a rapid, sensitive, and easy-to-use strategy for miRNA quantification, offering a robust tool for point-of-care testing and liquid biopsy applications.
耗时 1.10896 秒，为您在
49570523
条记录里面共找到 6844 篇文章 [XML]